West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
West Pharmaceutical Services, Inc. (WST) Return on equity
West Pharmaceutical Services, Inc.'s return on equity over the twelve months to 30 June 2026 was 19.1%, up 2.2 percentage points from fiscal 2025 (16.9%). Over the past ten years it has ranged from 9.65% (fiscal 2015) to 31.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 16.9% | (0.86) |
| FY2024 | 17.7% | (3.61) |
| FY2023 | 21.3% | (2.02) |
| FY2022 | 23.3% | (8.25) |
| FY2021 | 31.6% | 11.39 |
| FY2020 | 20.2% | 3.92 |
| FY2019 | 16.3% | 0.82 |
| FY2018 | 15.5% | 2.89 |
| FY2017 | 12.6% | (0.84) |
| FY2016 | 13.4% | 3.76 |
Against its own ten years
Low 9.65%
High 31.6%
Ten-year median
16.9%
Current reading's percentile
55
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation compare | 34.0% |
| RMD ResMed Inc. compare | 24.3% |
| WST West Pharmaceutical Services, Inc. | 19.1% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| BDX Becton, Dickinson and Company compare | 3.77% |
| ALC Alcon compare | 2.94% |
| RGEN Repligen Corporation compare | 1.99% |
| MDLN Medline Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −15.8% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement